MedTrace Logo

Medical Access Program for Patritumab Deruxtecan

NCT06099639 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-06-08

No results posted yet for this study

Summary

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

Conditions

  • Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Interventions

DRUG

HER3-DXd

5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes

Sponsors & Collaborators

Principal Investigators

  • Program Team Lead · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06099639 on ClinicalTrials.gov